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Available online 30 January 2019Background: Cytosolic 5′-nucleotidase 1A (NT5C1A) dephosphorylates non-cyclic nucleoside monophosphates
to produce nucleosides and inorganic phosphates. Here, we investigate NT5C1A expression in pancreatic ductal
adenocarcinoma (PDAC) and its impact on gemcitabine metabolism and therapeutic efficacy.
Methods:NT5C1A expression was determined by semiquantitative immunohistochemistry using tissuemicroar-
rays. Gemcitabine metabolites and response were assessed in several human and murine PDAC cell lines using
crystal violet assays, Western blot, viability assays, and liquid chromatography tandem mass-spectrometry
(LC-MS/MS).
Findings: NT5C1A was strongly expressed in tumor cells of a large subgroup of resected PDAC patients in two
independent patient cohorts (44–56% score 2 and 8–26% score 3, n= 414). In contrast, NT5C1A was expressed
at very low levels in the tumor stroma, and neither stromal nor tumoral expression was a prognostic marker for
postoperative survival. In vitro, NT5C1A overexpression increased gemcitabine resistance by reducing apoptosis
levels and significantly decreased intracellular amounts of cytotoxic dFdCTP in+NT5C1A tumor cells. Co-culture
experiments with conditionedmedia from+NT5C1A PSCs improved gemcitabine efficacy in tumor cells. In vivo,
therapeutic efficacy of gemcitabinewas significantly decreased and serum levels of the inactive gemcitabineme-
tabolite dFdU significantly increased in mice bearing NT5C1A overexpressing tumors.
Interpretation: NT5C1A is robustly expressed in tumor cells of resected PDAC patients. Moreover, NT5C1A medi-
ates gemcitabine resistance by decreasing the amount of intracellular dFdCTP, leading to reduced tumor cell ap-
optosis and larger pancreatic tumors inmice. Further studies should clarify the role of NT5C1A as novel predictor
for gemcitabine treatment response in patients with PDAC.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Research in context
Evidence before this study
Pancreatic ductal adenocarcinoma is highly refractory to systemic
therapies. Poor therapeutic response to gemcitabine in PDAC has
been attributed in part to altered drug metabolism, in particular re-
duced cellular uptake or rapid enzymatic inactivation. Indeed, high
expression of the human equilibrative nucleoside transporter
(hENT) has been shown to predict improved patient survival fol-
lowing gemcitabine treatment.
The 5′-nucleotidase (NT5) family of enzymes dephosphorylates
non-cyclic nucleoside monophosphates to produce nucleosides
and inorganic phosphates. Interestingly, NT5C1A is a previously
unrecognized gemcitabine inactivating enzyme that prevents
gemcitabine activation by dephosphorylating gemcitabine
monophosphate (dFdCMP).However, the detailed expression pat-
tern in PDAC patients and the role of NT5C1A in mediating resis-
tance to gemcitabine is currently unknown.
Added value of this study
The present study provides evidence that NT5C1A is strongly
expressed in tumor cells of resected PDAC patients. Mechanisti-
cally, we show that NT5C1A is implicated in gemcitabine resis-
tance in vitro and in vivo by decreasing the amount of
intracellular cytotoxic gemcitabine metabolites. Only a small frac-
tion of PDAC patients show NT5C1A expression in the tumor
stroma, and high expression in stromal cells may contribute to im-
proved gemcitabine sensitivity in tumor cells.
Implications of all the available evidence
We have elucidated the expression pattern and function of
NT5C1A in human and mouse PDAC using several in vitro and
in vivo models. Thus, our study introduces NT5C1A as
gemcitabine inactivating enzyme in PDAC and paves the way for
the evaluation of NT5C1A for stratified treatment approaches,
both for adjuvant as well as palliative therapy regimens.
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-FU 5-fluorouracil
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MPK AMP-activated protein kinase
AFs cancer-associated fibroblasts
C3 cleaved caspase-3
DA cytidine deaminase
M conditioned medium
0 day 0
API 4′,6-diamidino-2-phenylindole
CK deoxycytidine kinase
CTD deoxycytidylate deaminase
FdC 2′,2′-difluoro-2′-deoxycytidine
FdCMP 2′,2′-difluoro-2′-deoxycytidine monophosphate
FdCDP 2′,2′-difluoro-2′-deoxycytidine diphosphate
FdCTP 2′,2′-difluoro-2′-deoxycytidine triphosphateFdU 2′,2′-difluoro-2′-deoxyuridine
MEM Dulbecco's Modified Eagle Medium
NA deoxyribonucleic acid
BS fetal bovine serumgram(s)
hour(s)&E hematoxylin and eosin
A-tag hemagglutinin tag
Ent human equilibrative nucleoside transporter
RP horseradish peroxidase
SP90 heat shock protein 90
C immunocytochemistry
C immunohistochemistry
G immunoglobulin G
g kilogram
PC LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre
C-MS/MS liquid chromatography tandem mass-spectrometry
EM Minimum Essential Media
g milligrams
-MLV Moloney Murine Leukemia Virus
RNA messenger ribonucleic acid
TT 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide
M nanomolar
s non-significant
T5 5′-nucleotidase
T5C1A cytosolic 5′-nucleotidase 1A
BS phosphate buffered saline
DAC pancreatic ductal adenocarcinoma
M picomolar
SCs pancreatic stellate cells
RT-PCR quantitative real-time polymerase chain reaction
RM1 ribonucleotide reductase M1
EM standard error of mean
AM tumor-associated macrophages
MA tissue microarray
ME tumor microenvironment
.S. United States
B Western blot1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) is one of themost aggres-
sive solid human tumors. Due to the lack of early symptoms, around 80%
of patients are diagnosed with locally advanced or metastatic disease
rendering them inoperable [1–3]. Current statistics project pancreatic
cancer to become the second cause of cancer-related death in the U.S.
by the year 2030 [4].
Systemic treatment options have been of limited success since PDAC
is intrinsically highly refractory to medical therapies. Gemcitabine
monotherapy has been the standard of care for palliative and adjuvant
treatment for many years without providing clinically meaningful ef-
fects on overall survival [5]. More recently, intensified chemotherapy
regimens have emerged that can improve overall survival. To this end,
FOLFIRINOX (FOLinic acid, 5-FU, IRINotecan and OXaliplatin) and
gemcitabine plus nab-paclitaxel are available in the palliative setting
[6,7], and gemcitabine plus capecitabine (a 5-FU prodrug) was shown
to increase long-term survival as adjuvant treatment compared to
gemcitabine alone [8]. Nevertheless, therapy regimens like
FOLFIRINOX require a good performance status of the patient due to in-
creased toxicity [6]. However, despite the availability of intensified
treatment protocols, the prognosis for PDAC patients remains extremely
poor in comparison with other solid malignancies with median survival
times below one year in patients with advanced or metastatic disease
[9].
396 M.S. Patzak et al. / EBioMedicine 40 (2019) 394–405Poor therapeutic response to gemcitabine in PDAC has been attrib-
uted in part to altered drug metabolism, in particular, reduced cellular
uptake or rapid enzymatic inactivation [10–13]. Gemcitabine is a
hydrophilic drug that is administered as prodrug (2′,2′-difluoro
2′-deoxycytidine; dFdC) and cellular uptake is predominantly accom-
plished by human equilibrative nucleoside transporters (hENT).
Subsequently, the prodrug dFdC is phosphorylated to mono-, di- and
tri-phosphate (dFdCMP, dFdCDP and dFdCTP), blocking de novo DNA
synthesis by inhibition of ribonucleotide reductase (RRM), or terminat-
ing DNA chains through incorporation of dFdCTP into DNA [14]. The
rate-limiting activation step is the phosphorylation by deoxycytidine
kinase (dCK). Inactivation of gemcitabine and its metabolites is con-
ferred by cytidine deaminase (CDA), and other enzymes such as
deoxycytidylate deaminase (DCTD) [14,15]. Moreover, molecular com-
petition through increased levels of deoxycytidine triphosphate further
reduce the effective levels of gemcitabine [16].
The 5′-nucleotidase (NT5) family of enzymes dephosphorylates
non-cyclic nucleoside monophosphates to produce nucleosides and
inorganic phosphates. There are seven human NT5Cs of which
cytosolic NT5C1A is mainly expressed in muscle and heart [17]. Under
physiological conditions, NT5C1A regulates the pool of adenosine
monophosphate (AMP), which is, in turn, responsible for allosterically
stimulating AMPK activity [18,19]. In addition, NT5C1A is a previously
unrecognized gemcitabine inactivating enzyme that dephosphorylates
gemcitabine monophosphate (dFdCMP) to the prodrug dFdC, thus po-
tentially limiting the cytotoxicity of gemcitabine by decreasing the for-
mation of dFdCTP [20–22].
Notably, the role of nucleotidases that may mediate drug resistance
through dephosphorylation of nucleoside analogues has not been inves-
tigated in PDAC so far. We have recently described differential expres-
sion of NT5C1A in human and murine stromal and epithelial cells for
the first time in PDAC [23]. However, there are currently no data for
PDAC or any other solid tumor that implicates NT5C1A in therapeutic
resistance to gemcitabine. Here, we explored the expression pattern
and frequency of NT5C1A in two large and independent cohorts of
PDAC patients and determined the role of NT5C1A in mediating resis-
tance to gemcitabine using several in vitro and in vivo approaches.
2. Materials and methods
2.1. Cell lines and cell culture
The LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) mouse
model is a commonly used genetically engineered mouse model for
pancreatic cancer [24]. Thus, murine KPC cell lines were used for this
study. These cells were derived from KPC mice as previously described
[24]. KPC cells were maintained in culture according to standard proce-
dures in high glucose DMEMwith phenol red, supplemented with 10%
fetal bovine serum (FBS) and 1% non-essential amino acids. MEMwith-
out phenol red, supplemented with 10% FBS and 1% L-glutamine was
used for human L3.6pl cells. Immortalized murine PSCs from a previous
study [23] were cultured in high glucose DMEM with phenol red and
supplemented with 10% FBS.
Mycoplasma tests of KPC-BL6 cell lines and of L3.6pl cells were per-
formed prior to orthotopic transplantation and liquid chromatography
tandem mass-spectrometry (LC-MS/MS), respectively.
2.2. Establishment of cell lines stably expressing NT5C1A
KPC, L3.6pl cells, and PSCs were transfected with a pSG5-vector-
derivative containing the sequence of murine NT5C1A or a control plas-
mid without the NT5C1A insert. We followed the protocol as described
by Kari et al. [25] to generate the constructs. The pSG5-vector (a kind
gift of Prof. Johnsen, University Medical Center Goettingen) containing
an HA-tag upstream of a multiple cloning site, a P2A-sequence and a
hygromycin resistance gene was transfected into each cell line asrecently described by our group [23]. The following hygromycin con-
centrations (Hygromycin B Gold, InvivoGen) were used for selection:
KPC1: 500 μg/ml, KPC2: 900 μg/ml, L3.6pl: 500 μg/ml, PSCs: 250 μg/ml.
For maintenance, only half of these concentrations were added to the
culture media.
2.3. Immunohistochemistry and immunocytochemistry
Mouse tissues were fixed in 10% neutral buffered formalin,
dehydrated and embedded in paraffin. 4 μm sections were cut from
the tissues and processed for H&E staining and immunohistochemistry
using standard protocols as previously described [23]. Pictures were
taken with 40× magnification with an Olympus DP27 camera and the
Olympus cellSens Entry 1.12 software.
Immunocytochemistry was performed for KPC cell lines as previ-
ously described [23]. Briefly, cells were fixed with methanol, perme-
abilized using triton X-100 and incubated with primary antibodies for
NT5C1A (Assay Biotech Cat# C15296, RRID:AB_10687827) and HA-tag
(Cell Signaling Technology Cat# 3724, RRID:AB_1549585) at 4 °C over-
night. Alexa Fluor®-conjugated secondary antibodies were used for de-
tection and slides were mounted using DAPI-containing mounting
solution (Vectashield®). Image acquisition was done utilizing a
Leica DMi8 microscope (Leica Microsystems CMS GmbH, Wetzlar,
Germany) and images were extracted with equal adjustments between
groups using Fiji/ ImageJ (Fiji, RRID:SCR_002285) [26]. A detailed list of
all antibodies and dilutions can be found in the supplementary
materials.
2.4. Tissue microarrays
Tissue microarrays (TMA) were obtained from the Department of
Pathology, University Medical Center Goettingen (TMA-1, n = 77
patients) and the Department of Pathology, University Medical Center
Erlangen (TMA-2, n=337 patients) from postoperative PDAC patients.
Written consent was obtained from every patient prior to tissue collec-
tion and analysis. Expression levels of NT5C1Awere semi-quantitatively
analyzed by an experienced pathologist at each site from score 0 (no ex-
pression) to score 3 (strong expression). Immunohistochemistry was
performed using standard protocols with hematoxylin counterstaining.
TMA-1 staining was performed with citrate buffer pH 6.0, NT5C1A anti-
body (Assay Biotech Cat# C15296, RRID:AB_10687827, 1:100), and the
VECTASTAIN®ABC Rabbit Kit with ImmPACT DAB Peroxidase Substrate
Kit (Vector Laboratories). Pro Taqs II Antigen Enhancer pH 9.5, NT5C1A
antibody (Atlas Antibodies Cat#HPA050283, RRID:AB_2681072, 1:100)
and the ImmPress Reagent Kit Anti-Rabbit IgG (Vector Laboratories)
with AEC-Plus Substrate-Chromogen (Dako Denmark A/S) were used
for TMA-2.
2.5. Western blot analysis
Western blot analyses were performed as previously described with
35 μg of protein [23]. Membranes were incubated with chemilumines-
cence substrate Plus-ECL (PerkinElmer Inc.) or Ultra-ECL (for CC3-
detection) and protein bands were detected at the ChemiDoc™ XRS+
imaging system (Bio-Rad Laboratories GmbH) using Image Lab Soft-
ware (RRID:SCR_014210, version 5.2.1). Quantification was performed
using the rectangle volume tool of the Image Lab Software. Values
were normalized to HSP90 expression and to the expression of un-
treated protein lysates. Murine muscle lysate was used as positive con-
trol for NT5C1A expression (3 μg). A detailed list of primary and
secondary antibodies is listed in supplementary materials.
2.6. Crystal violet cell proliferation assay
The commonly used crystal violet staining [27]wasperformed to de-
termine the sensitivity of transfected cell lines towards gemcitabine and
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sity of 2000 cells (KPC cells, PSCs) and 7500 cells (L3.6pl) in 24-well
plates and were allowed to attach for 24 h. Subsequently, cells were
treated with increasing concentrations of gemcitabine-hydrochloride
or paclitaxel, respectively. Cells were treated for six days and treatment
media was renewed every other day. Finally, cells were washed with
PBS, fixed with methanol and subsequently stained with crystal violet
solution (0.1% in 20% ethanol). Regarding gemcitabine, three (tumor
cell lines) and two (PSCs) independent experiments were performed,
respectively. For paclitaxel treatment, two independent assays were
carried out. Quantification of crystal violet assays was performed using
10% acetic acid to solubilize crystal violet stain and subsequent photo-
metric measurements of diluted samples at 595 nm. Results were nor-
malized to untreated control cells.
2.7. Preclinical in vivo study using a syngeneic orthotopic mouse model
All animal procedureswere conducted according to institutional and
national regulations. Housing conditions for the mice were at a 12 h
light and 12 h dark cycle. C57BL/6-J mice (Charles River) were used
for orthotopic transplantation studies. Mice were transplanted at the
age of eight weeks and randomized into four groups before transplanta-
tion (n = 7 per group). Stably transfected syngeneic KPC-BL6 cells
(+NT5C1A) and respective control cells were trypsinized, and
150,000 viable cells were mixed in an equal volume of matrigel prior
to transplantation. A total volume of 40 μl was injected into the tail of
the pancreas. Small animal high-resolution ultrasound was performed
as previously described [28]. In brief, a Visual Sonics Vevo 2100 High
Resolution Ultrasound System, including imaging stage and anesthesia
line (FUJIFILM VisualSonics Inc., Canada) was used for the study with a
Vevo 2100 MicroScan Transducer MS-550-D (22-55 MHz). Mice were
anesthetized with 2% isoflurane during ultrasound examinations.
Treatment with gemcitabine or saline started seven days after sur-
gery. Mice were then sacrificed on day 14 of the treatment, with injec-
tions on day 0, 3, 7, 10, and 13. Gemcitabine-hydrochloride was
administered intraperitoneally at 100 mg/kg body weight. Comparable
volumes of salinewere injected for control animals. Micewereweighed
three times per week. As previously described, mice were sacrificed ex-
actly 2 h after the last gemcitabine injection [29].
2.8. RNA preparation and qRT-PCR
RNA was extracted from cells using the PeqGold Total RNA kit
(Peqlab GmbH) according to the manufacturer's protocol. RNA concen-
trationwas determined using a nanophotometer (INTAS P330) and 1 μg
was used for cDNA preparation. Recombinant RNasin ribonuclease in-
hibitor (Promega GmbH) was added to the extracted RNA samples
prior to reverse transcription.M-MLV reverse transcriptase (Invitrogen)
and poly(dT)15 oligo primers (Roche Diagnostics GmbH) were used for
cDNA preparation. Myoblast-mRNA was kindly provided by Prof. J.
Schmidt, University Medical Center Goettingen and used as a positive
control for human NT5C1A expression. Murine muscle RNA served as
positive control for murine NT5C1A expression. TaqMan probes for
NT5C1A and for ß-actin are listed in supplementary materials.
2.9. Liquid chromatography tandem mass-spectrometry (LC-MS/MS)
For LC-MS/MS analysis of gemcitabine treated cells, 700,000 cells
were seeded into 6-well plates. 24 h later, cells were exposed to 1 μM
of gemcitabine-hydrochloride for 2 h. Homogenates of cell pellets
were analyzed for native dFdC and its triphosphate metabolite dFdCTP
by LC-MS/MS according to a previously published protocol [30,31].
Three biological replicates, with 2–3 technical replicates were analyzed
for gemcitabine metabolites. Serum samples from orthotopically
transplanted mice were taken 2 h after administering the lastgemcitabine dose and were analyzed for 2′,2′-difluoro-2′-deoxyuridine
(dFdU).2.10. Statistical analysis
GraphPad Prism (RRID:SCR_002798, version 7.03) was used for sta-
tistical analysis. Data are shown as mean± SEM. Statistical significance
was considered for p b .05, with *b0.05, **b0.01, and ***b0.001. Two-
tailed Student t-test was used for analysis, if not stated otherwise.3. Results
3.1. NT5C1A is strongly expressed inmurine and human PDACand is not as-
sociated with overall survival
Comprehensive expression data of NT5C1A in PDAC are not available
so far. To address this question, we employed two independent TMAs of
resected PDAC specimens. A semi-quantitative scoring system ranging
between score 0 (no expression) to score 3 (strong expression)was uti-
lized. A relevant subgroup of patients expressed NT5C1A at high levels
(score 2 and 3). 56% of all patients showed moderate expression
(score 2) of NT5C1A in the epithelial compartment of the tumors and
8% expressed NT5C1A at high levels (score 3) in TMA-1with 77 samples
(Fig. 1A). A larger TMA dataset with 337 samples confirmed these find-
ings with 44% scored with 2, and 26% of all patient samples had score 3
(Fig. 1B). Furthermore, only 13.0% (TMA-1) and 4.5% (TMA-2) of all tu-
mors did not show immunoreactivity against NT5C1A (Fig. 1A–C). Inter-
estingly, NT5C1A expression did not correlate with overall survival in
either TMA, comparing low NT5C1A expression (score 0 and 1) with
high expression levels of NT5C1A (score 2 and 3). Median survival
was 18.5 vs. 15 months in TMA-1 (p = .5), and 17 vs. 16.4 months in
TMA-2 (p = .3) (Fig. 1D and E). Moreover, KPC pancreatic tumors
were analyzed for NT5C1A expression and robust expression could be
confirmed by IHC staining in the majority of samples, and was already
present in early stages of pancreatic cancer (Fig. 1F). The expression
was confirmed by qRT-PCR to determine mRNA levels for NT5C1A in
KPC bulk tissue. As expected no expressionwas found in healthy control
pancreata (Fig. 1G).3.2. NT5C1A expression in murine and human PDAC cell lines
In analogy to our published data about gemcitabine drug scavenging
of stromal cells [23], we hypothesized that high levels of NT5C1A
within the tumor cells might be involved in chemoresistance in PDAC,
in particular gemcitabine resistance. To this end, NT5C1A may affect
gemcitabine metabolism by reversing the initial phosphorylation step
of dFdC to dFdCMP, resulting in decreased levels of cytotoxic dFdCTP.
To test this hypothesis, NT5C1A expression was investigated in murine
and human pancreatic cancer cell lines. Interestingly, murine and
human pancreatic cancer cells revealed only low levels of NT5C1A ex-
pression in vitro compared to robust expression levels in the tumor tis-
sue (Fig. S1A and B). Therefore, NT5C1Awas stably expressed inmurine
KPC cell lines (KPC1 and KPC2=KPC-BL6) and in the human L3.6pl cell
line. Stable cell lines were established using a pSG5-vector derivative
with subsequent hygromycin selection. NT5C1A expression in stable
cell lines was validated by Western blot analysis, immunocytochemis-
try, and qRT-PCR analysis (Fig. 2A–D). NT5C1A and the integrated HA-
tag were robustly expressed in transfected cells. Control cells that
were transfected with an empty vector, were shown to express endog-
enous NT5C1A at low levels and did not showHA-tag expression by im-
munocytochemistry (Fig. 2A and B). Additionally, qRT-PCR analysis was
employed to confirm mRNA expression of NT5C1A, and Western blot
analysis was used to determine NT5C1A protein levels in the overex-
pressing cells (Fig. 2C and D).
Fig. 1. Expression of cytosolic 5′-nucleotidase 1A (NT5C1A) in resected PDAC patients and in the KPC mouse model. Tissue microarrays (TMA) from A) Goettingen (TMA-1, n= 77) and
B) Erlangen (TMA-2,n=337). Score 0=noNT5C1Aexpression, score 3 indicates strong intratumoral expression ofNT5C1A. C) Representative images of TMA-1 for tumoral expression of
NT5C1A scoredwith score 0, score 1, score 2, and score 3 (from left to right). Scale bars 20 μm. D) and E) Survival analysis of patients from theGoettingen TMA cohort (D) and the Erlangen
TMA cohort (E). Median survival of TMA-1with low= 18.5months (n=27) and high= 15months (n=38; p= .5, log-rank test) and of TMA-2with low= 17months (n=101) and
high= 16.4months (n=235; p= .3, log-rank test). F) Representative images of NT5C1A immunohistochemistry in KPCmice with PanINs (upper image) and invasive carcinoma (lower
image). Scale bars 20 μm. G) NT5C1A-mRNA expression in KPC bulk tissue (n= 3mice) and control normal pancreas (n= 2mice). Mean± SEM of two technical replicates is shown for
each mouse. Murine muscle was used as positive control and values were normalized to the housekeeping gene β-actin.
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Fig. 2. Recombinant expression of NT5C1A in human and murine pancreatic cancer cell lines. A) and B) Representative images of two biological replicates of immunocytochemistry
staining for NT5C1A and HA-tag. Robust staining is shown for HA-tag (A, lower panel) and NT5C1A (B, lower panel) in transfected KPC-BL6 (=KPC2) cells. No staining of HA-tag (A,
upper panel) and low endogenous NT5C1A expression (B, upper panel) were detected in vector control cells (n = 2), scale bars 50 μm. C) Quantitative RT-PCR analysis confirmed
overexpression of NT5C1A in transfected cells. Diagram indicates mean ± SEM of three biological replicates. Murine muscle sample was used as positive control and values were
normalized to the housekeeping gene β-actin. D) Western blot analysis confirmed NT5C1A protein expression in transfected tumor cells with hardly any expression in vector control
cells. Robust expression of HA-tag is shown in all +NT5C1A cell lines. Representative image of three independent experiments is shown. Murine muscle lysate was used as positive
control for NT5C1A expression.
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Fig. 3. High levels of NT5C1A increase chemotherapeutic resistance towards gemcitabine in pancreatic cancer cells. A) Pharmacokinetic analysis of gemcitabine metabolites in murine
PDAC cells. Murine KPC-BL6 cells (A) and human L3.6pl cells (B) (+NT5C1A) and respective control cells (+vector) were simultaneously treated with 1 μM gemcitabine-
hydrochloride for 2 h. The concentration of the active gemcitabine metabolite dFdCTP (KPC-BL6: 27.3 vs. 9.4 pM per 1*106 cells, p= .0008 and L3.6pl: 67.3 vs. 30.8 pM per 1*106 cells,
p = .021) and of native gemcitabine dFdC (C) were determined in homogenates of cell pellets using LC-MS/MS-analysis. Three biological replicates and the mean value are shown.
Each dot represents the mean of three (KPC-BL6) or two (L3.6pl) technical replicates, respectively. All dFdC measurements of KPC-BL6 control cells were below the level of
quantification, thus the values were set to zero. D) Murine and human pancreatic cancer cell lines were incubated with different concentrations of gemcitabine for six days. Crystal
violet staining was more pronounced in cell lines with high NT5C1A expression. Three independent experiments, with each two technical replicates, were performed for all cell lines
shown. E) Quantification of crystal violet assays for KPC1 cells using 10% acetic acid to solubilize crystal violet stain and photometric measurements at 595 nm. Results were
normalized to untreated control cells. Two-way ANOVA with Sidak's multiple comparisons test was performed (12 nM: p = .0007, 20 nM: p b .0001). Graph shows mean ± SEM.
F) Western blot analysis revealed reduced cleaved caspase-3 (CC3) protein levels in NT5C1A-expressing cells following gemcitabine treatment for 24 h. Strong NT5C1A and HA-tag
expression was demonstrated in the +NT5C1A-cell line. Three independent experiments were performed. G) Quantification of CC3 protein expression in these three Western blot
analyses. Two-way ANOVA with Sidak's multiple comparisons test was performed (30 nM: p= .249, 50 nM: p= .002). Graph shows mean ± SEM.
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expression
NT5C1A dephosphorylates gemcitabine monophosphate (dFdCMP)
to the prodrug dFdC, thus potentially limiting the cytotoxicity of
gemcitabine by increasing the pool of dFdC and decreasing the amount
of cytotoxic dFdCTP. To test the implication of NT5C1A on gemcitabine
metabolism in pancreatic cancer we analyzed gemcitabine metabolites
in cell pellets upon gemcitabine treatment using LC-MS/MS. The con-
centrations of the native form of gemcitabine dFdC as well as the tri-
phosphate, the active metabolite of gemcitabine (dFdCTP) were
measured using a previously established protocol [30,31]. Following
NT5C1A overexpression in the murine KPC-BL6 cell line, upon 2 h of
gemcitabine treatment, the dFdCTP concentration was significantly re-
duced compared to control cells (27.3 vs. 9.4 pM per 1*106 cells, p =
.0008) (Fig. 3A). Equivalent results were seen for the human L3.6pl
cell line (67.3 vs. 30.8 pM per 1*106 cells, p= .021) (Fig. 3B). Interest-
ingly, intracellular dFdC levels were only detectable in the NT5C1A-
overexpressing KPC-BL6 cells, all values in the vector control cells
were below the limit of quantification (Fig. 3C). Thus, our findings sug-
gest a significant contribution of NT5C1A towards the availability of ac-
tive gemcitabine metabolites in PDAC, and possibly gemcitabine
resistance.
3.4. NT5C1A overexpression confers chemotherapeutic resistance towards
gemcitabine in vitro
We showed that NT5C1A decreases the concentration of dFdCTP
in vitro, and thus hypothesized that NT5C1A may be an important can-
didate inmediating gemcitabine resistance. Using crystal violet cytotox-
icity assays for two murine KPC cell lines as well as the human L3.6pl
pancreatic cancer cell line, we found that NT5C1A expression reverts
chemosensitivity in a concentration-dependent manner in all cell lines
(Fig. 3D and E, Fig. S2A and B). In contrast, all cell lines were still sensi-
tive to treatment with paclitaxel, which is another important chemo-
therapeutic agent for the treatment of pancreatic cancer patients
(Fig. S3A and B). To confirm and further clarify the involvement of
NT5C1A in gemcitabine resistance, we performedWestern blot analysis
for cleaved caspase-3 (CC3) protein levels upon gemcitabine treatment.
Gemcitabine-induced CC3-levels were reduced by factor 4 following
recombinant NT5C1A expression in KPC1 cells (Fig. 3F and G). Similar
results were obtained for the KPC-BL6 cell line (factor 2, Fig. S2C and
D). These results confirmed the impact of NT5C1A on gemcitabine resis-
tance in vitro.
3.5. NT5C1A expression and function in the tumor stroma
With the objective to obtain a more comprehensive picture of the
clinical situation regardingNT5C1A, we analyzed both TMAs for stromal
NT5C1A expression. The same scoring systemwas employedwith score
0 indicating no stromal expression of NT5C1A and score 3 indicating
strong expression of NT5C1A. The proportion of PDAC patients without
stromal NT5C1A expression was between 87.7% in TMA-1 (n=77) and
47.3% in TMA-2 (n = 330). Low expression was detected in 11.0%
(TMA-1) and 33.3% (TMA-2) of these patients. Interestingly, high scores
[2 and 3] of stromal NT5C1A was only given to the samples of 1.4%
(TMA-1) or 19.4% (TMA-2) of all patients (Fig. 4A–C). Consistent with
the tumor data, stromal NT5C1A expression was not a prognostic
marker. Themedian post-surgical survival timewas 15.2months for pa-
tients that did not express NT5C1A (n= 156) in the tumor stroma and
17.3 months for all other patients (n= 173; p= .3, TMA-2) (Fig. S4F).
Due to the lack of more detailed treatment details, it remains to be an-
swered whether stromal NT5C1A might be a predictive marker for
gemcitabine response in PDAC patients. As shown by our group previ-
ously, NT5C1A is expressed at very low levels in cancer-associatedfibro-
blasts (CAFs) and pancreatic stellate cells (PSCs) [23]. Furthermore,PSCs do not differ significantly regarding intracellular dFdCTP accumu-
lation compared to CAFs [23]. Therefore, two PSC cell lines were stably
transfected and + NT5C1A cells and vector control cells were analyzed
by Western blot as previously shown [23], and also by immunocyto-
chemistry and qPCR. HA-tag expression and robust expression of
NT5C1Awas confirmed in the+NT5C1A-cells (Fig. S4A–D). Crystal vio-
let staining showed increased resistance of NT5C1A expressing PSCs to
gemcitabine treatment (Fig. 4D and E, Fig. S4E). Considering our previ-
ously published findings that +NT5C1A-PSCs accumulate significant
lower amounts of intracellular gemcitabine triphosphate [23], we
hypothesized that gemcitabine availability would be significantly in-
creased in the supernatant of NT5C1A-PSCs. To test this, MTT assays
with conditioned media (CM) of transfected PSCs were performed.
PSCs were incubated with 25 nM of gemcitabine-hydrochloride for
24 h and CM was then transferred to two KPC tumor cell lines
(Fig. 4F). Cell viability was determined 72 h later and demonstrated sig-
nificantly decreased tumor cell viability with CM of +NT5C1A-PSCs,
compared to vector control cells with only endogenous levels of
NT5C1A. In the two KPC cell lines the viability decreased to 73% and
75% respectively (KPCa: p= .003 and KPCb: p= .047) (Fig. 4G).
3.6. NT5C1A expression mediates chemoresistance in vivo
Finally, we aimed to investigate whether NT5C1A mediates
chemoresistance in vivo. To this end, we employed a syngeneic,
orthotopically transplantedmousemodel using C57BL/6-Jmice and sta-
bly transfected KPC-BL6 cells. Seven days after tumor cell transplanta-
tion, mice were treated with gemcitabine or saline for 14 days
(Fig. S5A). High-resolution small animal ultrasound screening was per-
formed on day 9 of the treatment to verify tumor growth upon trans-
plantation (Fig. 5A). Intratumoral NT5C1A and HA-tag expression
were confirmed by immunohistochemistry and showed robust protein
levels in tumors derived from stably transfected cells (Fig. 5B). Tumor
growth measured by absolute tumor weights was significantly in-
creased following gemcitabine treatment in NT5C1A-overexpressing
tumors compared to tumors derived from vector control cells (0.25 g
vs. 0.37 g; p= .03) (Fig. 5C and D). However, the overall number of ap-
optotic cells within the tumor was not significantly decreased upon
NT5C1A overexpression (data not shown). Moreover, serum levels of
dFdU, the inactive gemcitabinemetabolite, were significantly increased
in mice bearing NT5C1A-overexpressing tumors with median concen-
trations of 14.1 vs. 17.6 μM dFdU (p = .009) (Fig. 5F). These data
strongly support our hypothesis that high NT5C1A expression reduces
sensitivity to gemcitabine. Accordingly, and in line with the patient
data demonstrating NT5C1A not to be a prognostic marker (Fig. 1D
and E), we did not observe significant NT5C1A-dependent differences
in tumor growth upon saline treatment of mice (0.82 g vs. 0.99 g; p=
.07) (Fig. 5E). Additionally, comparing gemcitabine treated tumors to
saline treated tumors, we show that NT5C1A expression is not induced
by gemcitabine treatment (Fig. S5B).
4. Discussion
The advent of precision oncology concepts has shown extraordinary
treatment responses in several tumor entities such as melanoma, lung
and breast cancer. However, there are currently no established bio-
markers for PDAC patients in clinical routine that would assist to select
the best treatment option or to predict treatment response for individ-
ual patients [32]. Notably, several recent preclinical and clinical studies
suggested that gemcitabine transport and metabolism proteins are im-
plicated in treatment response and patient outcome andmay thus serve
as appropriate biomarkers to select patients for gemcitabine treatment.
For example, high hENT1 and dCK protein levels have been associated
with improved outcome of PDAC patients following gemcitabine treat-
ment [10–12,33,34]. In contrast, data from large randomized
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ated with survival upon gemcitabine treatment [10,34].
Here, we investigated the expression and function of NT5C1A, a pre-
viously unrecognized gemcitabine inactivating enzyme that has not
been reported to be expressed in any solid carcinoma before. To the
best of our knowledge, we are thefirst group to publish detailed expres-
sion data on NT5C1A in pancreatic cancer specimens. Interestingly,
NT5C1A was robustly expressed in the epithelial compartment of64–70% of PDAC patients, whereas 23–26% showed weak NT5C1A
expression, and 5–13% were devoid of NT5C1A immunoreactivity.
Although the functional implications have not been elucidated in
PDAC, NT5C1A expression had no prognostic effect on overall survival
of postoperative PDAC patients in our two cohorts. These results are in
linewith previously published data on hENT and other gemcitabineme-
tabolizing enzymes such as DCTD that also had no prognostic effect in
resected PDAC [11,34].
Fig. 4.NT5C1Aexpression and function inPDACstroma in vitro and in vivo. A) and B)Tissuemicroarray analysis forNT5C1A expression revealed very lowexpression in the tumor stromaof
resected PDAC patients. A semi-quantitative scoring system indicated no stromal expression with score 0 and strong stromal expression with score 3. TMA-1 from Goettingen (A) with
n = 77 patients (none scored with 3) and TMA-2 from Erlangen (B) with n = 330 patient samples. C) Representative immunohistochemistry of NT5C1A expression showing no
NT5C1A expression (score 0), low expression (score 1), and robust stromal expression (score 2) of TMA-1. Scale bars 20 μm. D) Murine PSCs were treated with increasing
concentrations of gemcitabine for six days and crystal violet assays were performed. The staining was more pronounced in NT5C1A expressing cell lines. Representative images of two
independent experiments, with each two technical replicates, are shown. E) Crystal violet stain intensity was quantified and results were normalized to untreated control cells. Graph
indicates mean ± SEM, two-way ANOVA with Sidak's multiple comparisons test was performed (7 nM: p b .035, 12 nM: p b .009, 20 nM: p b .0001, 35 nM: p= .007). F) and G) MTT
cell viability assay for KPC cell lines treated with conditioned medium (CM) of NT5C1A expressing PSCs and control CM. F) Schematic experimental overview. CM from PSCs
(+NT5C1A) and control PSCs (+vector) was obtained by preincubation with 25 nM gemcitabine-hydrochloride for 24 h. Subsequently, tumor cells were treated for 72 h with CM of
PSCs and viability was assessed using MTT cell viability assay. G) Tumor cell viability of two different murine KPC cell lines was significantly decreased following treatment with CM of
+NT5C1A-expressing PSCs (KPCa: 73%; p= .003 and KPCb: 75%; p= .047). Graphs indicate mean ± SEM of four biological replicates.
Fig. 5. NT5C1A expression mediates chemoresistance in vivo. A) Tumor detection was performed by small animal high-resolution sonography of orthotopically transplanted mice in all
groups on day 9 of treatment. Dotted line indicates the tumor. B) Representative immunohistochemistry showing HA-tag (left) and NT5C1A (right) stainings in vector (upper panel)
and NT5C1A transfected (lower panel) orthotopic tumors. Scale bars 20 μm. C) Tumor weights upon necropsy are shown with significantly increased tumor weights upon NT5C1A
overexpression in the gemcitabine treated cohort (n = 7 each; p = .03). Graph shows mean ± SEM. D) Necropsy pictures of orthotopically transplanted pancreatic tumors upon
gemcitabine treatment with vector (left) and stable expression of NT5C1A (right). E) NT5C1A expression in saline treated controls did not have a significant effect on tumor growth
(p = .07, n = 7 and 5, respectively). Graph shows mean ± SEM. F) The inactive gemcitabine metabolite dFdU was measured in serum samples of gemcitabine treated mice.
Significantly higher values were detected in mice with +NT5C1A tumors (median: 14.1 vs. 17.6 μM, p = .009, Mann-Whitney test). Single values of n = 6 mice per group and the
mean values are shown.
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404 M.S. Patzak et al. / EBioMedicine 40 (2019) 394–405An unexpected finding was that murine and human pancreatic can-
cer cells showed dramatically reduced expression of NT5C1Awhen cul-
tured in 2D. As we generated primary murine cell lines from the KPC
model, in which epithelial tumor cells showed robust NT5C1A expres-
sion in vivo, we speculate thatNT5C1Aexpression is regulated by signal-
ing cues from the tumor microenvironment (TME) that are lacking
during cell culture. The TME is abundant in PDAC and consists of large
amounts of collagen and hyaluronic acid, activated fibroblasts and
immune cells, including tumor associated macrophages (TAMs) [35].
Recent evidence from patient derived organoids (PDOs) have provided
compelling insights into tumor biology and tailored therapy approaches
[36,37]. This technique could be employed in future studies to under-
stand the differential expression of NT5C1A in 2D and 3D, and possibly
to use this knowledge for future patient stratification.
Notably, we provide first evidence that re-expression of NT5C1A, in
both murine and human PDAC cells, reduces sensitivity to gemcitabine
both in vitro and in vivo. Using LC-MS/MS techniques, we could directly
demonstrate the activity of NT5C1Aon gemcitabinemetabolismand the
subsequent reduction of tumor cell apoptosis. As expected, NT5C1A
overexpression did not induce chemotherapeutic resistance to pacli-
taxel, whose mechanism of action is independent of intracellular
phosphorylation. We had previously shown that recombinant overex-
pression of NT5C1A in PSCs reduced the intracellular amounts of ac-
tive gemcitabine, thus, potentially limiting the described drug
scavenging effect of PSCs [23]. Here, we provide a large dataset of pa-
tient samples, demonstrating not only overexpression in the majority
of tumor cells but also a lack of stromal NT5C1A expression in most
cases. In addition, we show for the first time that re-expression of
NT5C1A in PSCs leads to an improved sensitivity of gemcitabine in
tumor cells suggesting a reciprocal effect of NT5C1A, where high ex-
pression in the stroma and low expression in the tumor cells may
promote chemosensitivity. As stromal cells are not present in cell
culture and tumor cells express NT5C1A at low levels under 2D con-
ditions, our observations may partly explain the conundrum that
most human and murine pancreatic cancer cell lines respond very
well to gemcitabine in vitro but fail to exert meaningful anti-tumor
effects in genetically engineered mice or in human PDAC that both
harbor abundant desmoplasia.
It remains to be seen whether NT5C1A has any predictive effect fol-
lowing gemcitabine treatment in PDAC patients, and whether a combi-
nation with hENT quantification may yield any predictive benefit over
hENT or NT5C1A expression alone. In both TMA cohorts, a relevant frac-
tion of patients did not undergo adjuvant chemotherapy. Therefore, fur-
ther studies in prospectively collected, randomized and controlled
clinical specimens are warranted to determine the role of NT5C1A as a
potential novel predictor for gemcitabine-based therapies in PDAC.
Interestingly, a recent study provided evidence that TAMs may me-
diate chemoresistance in PDAC by upregulation of CDA, an important
gemcitabine inactivating enzyme, in tumor cells [13]. Whether this is
also true for other gemcitabine metabolizing enzymes such as NT5C1A
andDCTDhas not been investigated so far. Recentfindings suggestmul-
tiple cross-talking pathways between tumor cells, macrophages,
cancer-associated fibroblasts, and immune cells in stroma-driven
chemoresistance in PDAC [38–40]. Consistently, stroma-mediated can-
cer cell activation correlates with widespread increases in histone acet-
ylation atH3K9 andH3K27 residues, suggestive for profound alterations
in promoter and enhancer activation levels, although the transcriptional
consequences and therapeutic relevance of these findings remain
largely elusive [41]. Future studies will need to address whether the dy-
namic changes of NT5C1A expression in vitro and in vivomay be orches-
trated by epigenetic mechanisms that could also act as potential
therapeutic targets.
In conclusion, we have identified NT5C1A to be highly expressed in
the epithelial compartment of a relevant subgroup of PDAC patients.
Mechanistically, NT5C1A mediates gemcitabine resistance by dephos-
phorylating gemcitabine monophosphate, thus reducing the amountof cytotoxic gemcitabine metabolites intracellularly. Therefore, our
study paves the way for the evaluation of NT5C1A for stratified treat-
ment approaches in PDAC, both for adjuvant as well as palliative ther-
apy regimens.
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